BioMarin Completes Acquisition of Amicus Therapeutics
BioMarin Pharmaceutical Inc. said that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. "The completion of the Amicus acquisition advances BioMarin's strategy to strengthen and divers…
